Marianne Pavel.

Hazard ratios for disease progression or death generally favored lanreotide more than placebo in the predefined subgroups ., and Fig. S2 and S3 in the Supplementary Appendix). The exceptions were small subgroups , for which the hazard ratios got wide Continue reading Marianne Pavel.